Cortactin predicts poor survival in laryngeal carcinoma
Author Information
Author(s): Gibcus J H, Mastik M F, Menkema L, de Bock G H, Kluin Ph M, Schuuring Ed, van der Wal J E
Primary Institution: University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Hypothesis
Which gene correlates best with lymph node metastases and increased disease-specific mortality in laryngeal carcinomas?
Conclusion
High cortactin expression is the best predictor for shorter disease-specific survival in late stage laryngeal carcinomas.
Supporting Evidence
- High expression of cortactin correlates with increased disease-specific mortality.
- Cortactin expression is independent of cyclin D1 and FADD.
- Patients with high cortactin expression have a significantly worse prognosis.
Takeaway
Cortactin is a protein that helps predict how long patients with laryngeal cancer might live, especially if their cancer has spread to lymph nodes.
Methodology
Immunohistochemical analysis was performed on 106 laryngeal carcinoma samples to assess the expression of cyclin D1, FADD, and cortactin.
Potential Biases
Potential bias due to the selection of patients and the retrospective nature of the study.
Limitations
Follow-up was short or unavailable for some patients, and not all patients had sufficient tumor cells for analysis.
Participant Demographics
The study included 106 patients with late stage laryngeal squamous cell carcinoma, primarily larger tumors.
Statistical Information
P-Value
P=0.0006
Confidence Interval
95% CI, 4.6–27.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website